Indications |
Oral Hypertension Adult: As hydrochloride: Initially, 100 mg bid; increase gradually according to patient's response to 200-400 mg bid. Max dose: 2.4 g daily in 2-4 divided doses. Elderly: Initially, 50 mg bid. Intravenous Emergency treatment of hypertension Adult: As hydrochloride: 50 mg injected slowly for at least 1 min; repeat at 5-min intervals as necessary, up to 200 mg. Monitor BP and the patient should remain supine during and 3 hr after the procedure. Alternatively, 2 mg/min infusion at concentrations of 1 mg/ml or 2 mg/3 ml of a suitable diluent. Intravenous Hypertension in pregnancy Adult: As hydrochloride: Start infusion at a rate of 20 mg/hr, then doubled every 30 min until a favourable response is achieved or a dose of 160 mg/hr is reached. Intravenous Hypertension after myocardial infarction Adult: As hydrochloride: Start infusion at a rate of 15 mg/hr, then increase gradually until a favourable response is obtained or a dose of 120 mg/hr is reached. Intravenous Hypotensive anaesthesia Adult: As hydrochloride: Initially, 10-20 mg; increase at 5-10 mg increments if satisfactory hypotension is not achieved after 5 minutes. Administer higher initial doses if halothane anaesthesia is not used. |
Contraindications |
2nd and 3rd degree heart block, cardiogenic shock, obstructive airway disease e.g. bronchial asthma, uncompensated heart failure, severe bradycardia, sick sinus syndrome, Prinzmetal's angina, severe peripheral arterial disease. |
Warnings / Precautions |
Phaeochromocytoma, compensated heart failure, nonallergic bronchospasm. Avoid abrupt withdrawal. DM. Hepatic impairment. Perform LFTs. Elderly. Pregnancy and lactation. |
Adverse Reactions |
Orthostatic hypotension, dizziness, fatigue, vertigo, paraesthesia, headache, nasal stuffiness, dyspnoea, diarrhoea, abdominal pain, sexual dysfunction, dyspepsia, nausea, vomiting, scalp tingling, rash, increased transaminases, nightmares, worsening of intermittent claudication. Potentially Fatal: Hepatic injury. |
Drug Interactions |
Increased bioavailability with cimetidine. Decreased bioavailability with glutethimide. Increased incidence of tremors with TCAs. Additive hypotensive effect with nitroglycerin. Potentially Fatal: Increased risk of bradycardia with drugs that slows AV conduction. Synergistic hypotensive effect with halothane. See Below for More labetalol Drug Interactions |
Lab Interactions |
False-positive results in fluorimetric analysis of urinary catecholamines. |
Mechanism of Actions |
Labetalol competitively inhibits the adrenergic stimulation of β-receptors within the myocardium, bronchial and vascular smooth muscle, and α1-receptors within vascular smooth muscle. It also has some intrinsic β2-agonist and membrane-stabilising activity. Absorption: Absorbed readily from the GIT (oral); peak plasma concentrations after 1-2 hr. Bioavailability increased by food. Distribution: Protein-binding: 50%. Crosses the blood-brain barrier, placenta and enters breast milk. Metabolism: Extensive first-pass metabolism. Excretion: Via urine (as metabolites and traces of unchanged drug); also via faeces. Elimination half-life: 8 hr (steady state), 5.5 hr (IV infusion). |
Administration |
Should be taken with food. (Take immediately after meals.) |
Storage Conditions |
Intravenous: Store at 2-30°C (36-86°F). Oral: Store at 2-30°C (36-86°F). |
ATC Classification |
C07AG01 - labetalol ; Belongs to the class of alpha and beta blocking agents. Used in the treatment of cardiovascular diseases. |
Storage |
Intravenous: Store at 2-30°C (36-86°F). Oral: Store at 2-30°C (36-86°F). |
Available As |
|
Labetalol
Post Review about Labetalol Click here to cancel reply.
Labetalol Containing Brands
Labetalol is used in following diseases
Drug - Drug Interactions of Labetalol
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.